Discussion Paper: Research Priorities for Implementing Long-acting Injectable Cabotegravir for PrEP in Australia

This discussion paper provides a background on long-acting injectable Cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP). The paper outlines research priorities for implementing CAB-LA in Australia and was used to consult with Australian HIV Stakeholders. Findings from the Kirby Institute at UNSW Sydney, and Alfred Health in Melbourne, are reported on a range of formative research that investigated preferences and opinions of CAB-LA from community members, HIV stakeholders, and service providers. The discussion paper then explores several challenges, questions, and issues related to CAB-LA implementation, asking readers to consider these issues in the context of designing a potential implementation science trial.